AB Science: European patent accepted

(CercleFinance.com) - AB Science announces that the European Patent Office has accepted a patent for methods of treating sickle cell disease with masitinib, its lead compound, on the basis of preclinical results.


This patent protects the intellectual property of masitinib until November 2040.

Professor Olivier Hermine stated that masitinib could offer 'a promising new option for treating sickle cell disease and its severe complications, including acute chest syndrome'.

Sickle cell disease is an inherited disorder that affects red blood cells, and masitinib is designed to treat severe forms of the disease, accounting for around 65% of cases.



Copyright (c) 2024 CercleFinance.com. All rights reserved.